Orchestra BioMed is a biomedical innovation company focused on developing advanced therapeutic solutions to address significant unmet medical needs, particularly in the fields of hypertension and atherosclerotic artery disease. Their flagship technologies include BackBeat Cardiac Neuromodulation Therapy™ (BackBeat CNT) and Virtue® Sirolimus AngioInfusion™ Balloon (SAB). BackBeat CNT is an investigational bioelectronic therapy aimed at providing a substantial and lasting reduction in blood pressure by modulating the autonomic nervous system. This innovative approach targets hypertension, a major global health risk. 

The Virtue SAB is a patented drug/device combination designed for treating artery disease by delivering an extended-release formulation of sirolimus during balloon angioplasty, eliminating the need for balloon coating or permanent implants. This technology has received Breakthrough Device Designation, highlighting its potential to improve outcomes in various coronary and peripheral artery conditions. Both technologies exemplify Orchestra BioMed's commitment to creating high-impact solutions that can be rapidly adopted in the medical device market through strategic partnerships.

United States

Orchestra BioMed biomedical innovation company focused on developing transformative therapeutic products for large unmet clinical needs in procedure-based medicine.

Orchestra BioMed

Company Details